Halle (saale)

• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host disease. Ended
  2023-507960-38-00 4 2022-06-01 Acute graft versus host disease (aGVHD)
• GRAPPA Ended
  2023-510441-24-00 5 2022-01-28 Graft Vs Host Disease Peripheral Blood Stem Cell Transplantation AML M
• A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Interm … Ended
  2024-516296-32-00 3 2021-11-11 Myelodysplastic Syndromes (MDS)
• An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed … Ended
  2024-512717-41-00 4 2021-10-01 Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial (A … Ended
  2024-518182-10-00 5 2021-01-13 Acoustic schwannoma
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre … Ended
  2024-517166-42-00 4 2020-05-29 Diffuse large B-cell lymphoma (DLBCL)
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastat … Ended
  2024-515045-42-00 4 2018-04-23 Progressive well-differentiated metastatic neuroendocrine tumors of th
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe … Ended
  2023-504209-35-00 5 2018-04-04 Early-Stage Resectable Non-small cell lung cancer (NSCLC)
• A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MD … Ended
  2023-507154-32-00 1 2017-02-17 Myelodysplastic Syndromes (MDS)
• A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone … Ended
  2024-512474-98-00 5 2016-11-07 Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melan … Ended
  2024-516073-74-00 6 Unresectable or metastatic melanoma with a BRAF V600 mutation (inopera

Showing 193–213 of 213 trials